| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T9 |
0-117 |
Sentence |
denotes |
The recent emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) is responsible for a worldwide pandemic. |
| T10 |
118-267 |
Sentence |
denotes |
Given the global health emergency, drug repositioning is the most reliable option to design an efficient therapy for infected patients without delay. |
| T11 |
268-454 |
Sentence |
denotes |
The first step of the viral replication cycle [i.e. attachment to the surface of respiratory cells, mediated by the spike (S) viral protein] offers several potential therapeutic targets. |
| T12 |
455-602 |
Sentence |
denotes |
The S protein uses the angiotension-converting enzyme-2 (ACE-2) receptor for entry, but also sialic acids linked to host cell surface gangliosides. |
| T13 |
603-843 |
Sentence |
denotes |
Using a combination of structural and molecular modelling approaches, this study showed that chloroquine (CLQ), one of the drugs currently under investigation for SARS-CoV-2 treatment, binds sialic acids and gangliosides with high affinity. |
| T14 |
844-964 |
Sentence |
denotes |
A new type of ganglioside-binding domain at the tip of the N-terminal domain of the SARS-CoV-2 S protein was identified. |
| T15 |
965-1146 |
Sentence |
denotes |
This domain (111–158), which is fully conserved among clinical isolates worldwide, may improve attachment of the virus to lipid rafts and facilitate contact with the ACE-2 receptor. |
| T16 |
1147-1315 |
Sentence |
denotes |
This study showed that, in the presence of CLQ [or its more active derivative, hydroxychloroquine (CLQ-OH)], the viral S protein is no longer able to bind gangliosides. |
| T17 |
1316-1472 |
Sentence |
denotes |
The identification of this new mechanism of action of CLQ and CLQ-OH supports the use of these repositioned drugs to cure patients infected with SARS-CoV-2. |
| T18 |
1473-1655 |
Sentence |
denotes |
The in-silico approaches used in this study might also be used to assess the efficiency of a broad range of repositioned and/or innovative drug candidates before clinical evaluation. |
